Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 16/20 | 0.47 |
| ▸ | CLK2 | P49760 | 6/20 | 0.47 |
| ▸ | CLK3 | P49761 | 6/20 | 0.47 |
| ▸ | GSK3B | P49841 | 6/20 | 0.47 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.45 |
| ▸ | CLK1 | P49759 | 2/20 | 0.45 |
| ▸ | MELK | Q14680 | 1/20 | 0.44 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.44 |
| ▸ | WNT1 | P04628 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30398955 | 1.00 | FLT3 (0.48) | FLT3DYRK1ACLK2CLK3GSK3B | |
| SCHEMBL30400272 | 0.91 | EGFR (0.48) | DYRK1AGSK3BMAPK7DYRK1BCLK1 | |
| SCHEMBL26175108 | 0.91 | EGFR (0.48) | DYRK1AGSK3BMAPK7DYRK1BCLK1 | |
| SCHEMBL26175149 | 0.91 | MAPK7 (0.49) | FLT3DYRK1ACLK2CLK3GSK3B | |
| SCHEMBL30400780 | 0.91 | MAPK7 (0.49) | FLT3DYRK1ACLK2CLK3GSK3B | |
| SCHEMBL30398632 | 0.90 | DYRK1A (0.48) | DYRK1ACLK2CLK3GSK3BMAPK7 | |
| SCHEMBL26175150 | 0.90 | DYRK1A (0.48) | DYRK1ACLK2CLK3GSK3BMAPK7 | |
| SCHEMBL30400698 | 0.89 | DYRK1A (0.48) | DYRK1ACLK2CLK3GSK3BMAPK7 | |
| SCHEMBL26175115 | 0.89 | DYRK1A (0.48) | DYRK1ACLK2CLK3GSK3BMAPK7 | |
| SCHEMBL30400661 | 0.85 | DYRK1A (0.48) | DYRK1ACLK2CLK3GSK3BMAPK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | FLT3 1398/4885DYRK1A 1/4885CLK2 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.